Vitrolife, a medical technology group, completed the acquisition of Igenomix, a provider of genetic testing services, from EQT Partners, a global investment organization, for $1.48bn. "The combination of Igenomix and Vitrolife brings together two successful organizations that have been committed to innovation and customer service, which will create a global leader in reproductive health focusing on providing the best possible products and services for the IVF clinics to succeed in their strive to support patients becoming parents,” Thomas Axelsson, Vitrolife CEO.